Update from Cambridge Biomedical - Winter 2017
2017 marks 20 years of Science and Service® provided by Cambridge Biomedical. We celebrate 20 years of supporting patients and those who help them. Please appreciate our new logo design to signify this important milestone.
Message from our CEO
The year 2017, our 20th anniversary, gives me the opportunity to share with you a small part of the story of our incredible journey.
Initially called Cambridge Biomedical Research Group, CBRG was founded in 1997 by Dr. Michael Osband (1948-2001) as an innovative scientific research lab.
Patient testing was at the forefront of his research and has remained the foundation of our organization.
In 2002 we became a commercial laboratory. Working collaboratively with the 4 largest reference laboratories in the United States, we began developing and testing esoteric diagnostic assays.
In 2010 we shortened our name to Cambridge Biomedical Inc. and moved into a brand new facility. The state of the art laboratory and additional square footage allowed us to purchase new platforms. This new space and equipment, including: Luminex, Flow Cytometry, MSD, ELISA, and PCR allowed us the opportunity to serve the greater life sciences community. We successfully ventured into providing services to pharmaceutical and biotechnology organizations.
Providing bio analytical services to the life science industry, with a focus on science and service, is what has allowed us to be excited about what the next 20 years has to bring.
With gratitude to our team, clients, and patients who believe in Cambridge Biomedical, we hold that your trust in us is our strongest asset. Because of all of you, we are looking to a future for Cambridge Biomedical that builds on our legacy of innovation. Most importantly, we will continue to deliver the Science and Service® that our founder, Dr. Michael Osband, envisioned 2 decades ago.
Chairwoman and CEO
What is new in 2017
One way Cambridge Biomedical is celebrating its 20th Anniversary is by purchasing new equipment. We believe this type of investment is necessary for our clients and the patients that are relying on the newest and most reliable equipment.
We brought onboard 2 brand new QuickPlex SQ 120's and validated them in our labs this past January. This QuickPlex instrument is the newest multiplexing instrument from MSD. This will allow us to offer high-performance, electrochemiluminescence immunoassays. This compact system has been engineered for reliability.
Also this year we purchased a second ViiA™ 7 Real-Time PCR System. This system has the interchangeable blocks supporting 96-well, 384-well and Fast 96-well, well as TaqMan® Array Cards.
We estimate in the past 20 years we have developed and validated ~ 300 assays, run over 1 million samples and supported over 100 drug development organizations around the globe.
Visit Cambridge Biomedical's Website
New Biomarker Publication
For those who are interested in the FDA-NIF Biomarker Working group, they recently released a BEST (Biomarkers, EndpointS, and other Tools) Resource. This free 53 page document is can be downloaded directly from this link - https://www.ncbi.nlm.nih.gov/books/NBK326791/
Its chapters cover the following classes of biomarkers:
- Pharmacodynamic / Response
I hope you find this resource valuable. If you are interested in learning about our biomarker services, please click below to set up a meeting or call.
Submit a Biomarker Question to our Experts
New Greater Boston Area Support
Eric Wexler, M.B.A. joined Cambridge Biomedical as Business
Development Director, this past December. He concentrates on bioanalytical client services for the Greater Boston Area, where he has resided for the past 15 years. For over twenty-five years Eric has held positions of increasing responsibility as a research scientist for DuPont Agricultural Products, DuPont Merck Pharmaceuticals, DuPont Pharma, Bristol-Myers Squibb Medical Imaging, and Millennium Pharmaceuticals focusing on oncology, cardiovascular, CNS, and medical imaging.
Also during that time he trained researchers and clinicians how to use digital imaging for biomedical purposes as member of Adobe's Biomedical Image Advisory Group and the Digital Imaging Institute. For the past several years, as a business development professional, he supported the drug development efforts of a variety of organizations, from many top Pharmaceutical and Biotech companies to single person virtual drug development firms throughout North America, for SOLVO Biotechnology and QPS. He earned his degrees, B.A. degree in biology and M.B.A., from the University of Delaware.
Reach out to Eric
Meet with Cambridge Biomedical at the Following Events
- PBSS - April 24, Cambridge
- Biomarker Luncheon Hosted by Cambridge Biomedical - April 19, Cambridge, RSVP required
- PEGS - May 1-4, Booth #538, Boston